For an accessible version of this Press Release, please visit Q1 2026 revenues of ~$4.0 billion increased by 2% in U.S.

Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The late- ...